Background: Congenital nephrotic syndrome of Finnish type (NPHS1) is an autosomal recessive disorder characterized by severe proteinuria of intrauterine onset. Ninety-four percent of the Finnish NPHS1 chromosomes have been reported to carry either a 2-bp deletion in exon 2 (Fin Major ) or a nonsense mutation in exon 26 (Fin Minor ) of the NPHS1 gene. The high prevalence of only two mutations in the Finnish population enables the use of molecular techniques in the diagnosis of NPHS1 and for carrier screening. Methods and Results: We describe two different molecular methods for the detection of the NPHS1 mutations: a PCR-restriction fragment length polymorphism (PCR-RFLP) and a dual-color oligonucleotide ligation assay (OLA). The dual-color OLA, which enables simultaneous detection of the NPHS1 Fin Major and Fin Minor mutations, can be used for rapid analysis of large sets of samples. The analysis of 2004 Finnish blood samples revealed 34 carriers of the Fin Major mutation and 1 carrier of the Fin Minor mutation, indicating a carrier frequency of 1:59 (95% confidence interval, 1:89 -1:44) for the NPHS1 Fin Major mutation and 1:2004 (95% confidence interval, 0 to 1:677) for the NPHS1 Fin Minor mutation, respectively. Conclusion: PCR-RFLP and dual-color OLA are suitable for molecular diagnosis and carrier screening of the major mutations that cause NPHS1.
Congenital nephrotic syndrome of the Finnish type (CNF or NPHS1; 4 MIM 256300) is a recessively inherited severe disorder of infancy. It has been described worldwide, but more than one-half of the patients have been diagnosed in Finland, where its incidence is 1 in 8200 births (1 ) . NPHS1 is characterized by a large placenta (Ͼ25% of the birth weight), extremely severe proteinuria of an intrauterine onset, and a steroid-resistant nephrotic syndrome (2 ) . The only curative therapy is early bilateral nephrectomy followed by renal transplantation in the infancy (3 ) . The diagnosis of NPHS1 is based on the clinical features of the affected neonate and a typical histopathology of the kidneys. NPHS1 can be suspected prenatally on the basis of increased ␣-fetoprotein in the maternal serum or amniotic fluid (4, 5 ) . Recently, two major mutations in the NPHS1 gene, which encodes the membrane protein nephrin, have been described in the Finnish NPHS1 patients (6 ) . Based on the analysis of the affected neonates, 78% of the NPHS1 alleles have been reported to carry a 2-bp deletion in exon 2 (Fin Major ), and 16% of the alleles carry a nonsense mutation in exon 26 (Fin Minor ) (6 ) . The high prevalence of these two mutations simplifies the use of molecular techniques for the diagnosis of NPHS1 in the Finnish population. These techniques can also be used for the screening of asymptomatic carriers of this disorder, e.g., to find couples at risk of having an affected child.
We have developed two molecular methods for the detection of the NPHS1 Fin Major and Fin Minor mutations. In restriction fragment length polymorphism (RFLP) analysis of the PCR-amplified target DNA, the Fin Minor mutation abolishes a restriction site of the AvaII enzyme, thus preventing the digestion of the PCR product with this enzyme. The detection of the Fin Major mutation is based on the PCR-mediated generation of an artificial TaqI restriction site in the DNA template containing the Fin Major mutation. For the simultaneous detection of the Fin Major and Fin Minor mutations from a large number of samples, we utilized PCR followed by oligonucleotide ligation assay (PCR-OLA) (7, 8 ) . Both of the mutation sites were amplified in a single PCR reaction. The reporter probes for the Fin Major and Fin Minor mutation sites were labeled with different haptens, thus allowing simultaneous detection of two mutation sites in a single microplate well by ELISA. The applicability of the dual-color PCR-OLA for carrier screening of the Fin Major and the Fin Minor mutations of NPHS1 was tested by analyzing 2004 samples from eastern Finland.
Materials and Methods dna samples
Peripheral blood samples (n ϭ 2004) were collected in eastern Finland and made anonymous according to the institutional guidelines. The Split Second TM DNA Preparation Kit (Roche) was used to purify DNA samples from 250 L of EDTA blood. One DNA sample from a Finnish NPHS1 patient known to be homozygous for the Fin Major mutation and one from an individual homozygous for the Fin Minor mutation in the NPHS1 gene were kindly provided by Dr. Marjo Kestilä (University of Oulu, Oulu, Finland) and Prof. Karl Tryggvason (Karolinska Institut, Stockholm, Sweden). Genomic DNA was diluted to 50 mg/L with 10 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EDTA.
synthesis and modification of oligonucleotides
The oligonucleotides for the PCR and ligation reactions were synthesized using standard phosphoramidite chemistry. For PCR-RFLP, the target DNA in exon 2 (Fin Major site) was amplified using primers 5Ј-TTCTGGGCCCTGC-CTGAAATC-3Ј and 5Ј-CATCTTTGGCCCATTGCAC-3Ј, and the target DNA in exon 26 (Fin Minor site) was amplified using primers 5Ј-GGGGCTTGCATAGGGTCACT-3Ј and 5Ј-AGTGTCCCGCTCTCCTGTCC-3Ј. For PCR-OLA, the PCR primers described by Kestilä et al. (6 ) were used. The nucleotide sequences of the allele-specific and reporter oligonucleotides for the ligation reactions of the Fin Major and Fin Minor mutations, and the G3315A polymorphism site are shown in Table 1 . For detection of the sequence at the Fin Minor site, a mixture of two reporter probes (reporters 1 and 2) was used in the ligation reactions because of the polymorphism in the region of the reporter probe. The allele-specific oligonucleotides for OLA were modified with a 5Ј-biotin during the synthesis. All reporter oligonucleotides were 5Ј-phosphorylated, and the reporter probes for the Fin Major site and the polymorphic site were 3Ј-digoxigenin labeled, whereas the reporter probes for the Fin Minor site were 3Ј-fluorescein labeled by terminal transferase tailing reaction (8 ) .
pcr-rflp for detection of the Fin Minor and Fin Major mutations
The PCR reaction mixtures contained 25 ng of genomic DNA or 0.5 L of Split Second DNA sample, 50 ng of the amplification primers for the Fin Minor or the Fin Major mutation site, 6 nmol of each four deoxynucleotide triphosphates, 0.5 U of DyNAZyme II thermostable DNA polymerase (Finnzymes), 10 mmol/L Tris-HCl (pH 8.8 at 25°C), 1.5 mmol/L MgCl 2 , 50 mmol/L KCl, and 1 mL/L Triton-X-100 in a reaction volume of 30 L. The PCR amplifications were performed in an MJ Research PTC-100 thermal cycler (MJ Research). The cycling protocol included an initial temperature cycle of 95°C for 5 min, 85°C for the time needed to add the enzyme, 58°C for 30 s, and 72°C for 45 s, followed by a cycle of 94°C for 30 s, 58°C for 30 s, and 72°C for 45 s. A total of 30 cycles were performed, with final extension at 72°C for 10 min.
For detection of the Fin Major mutation by RFLP, 20 L of a restriction enzyme mixture containing 3 U of TaqI enzyme (Promega), 1ϫ Buffer E (6 mmol/L Tris-HCl, pH 7.5, 100 mmol/L NaCl, 6 mmol/L MgCl 2 , and 1 mmol/L dithiothreitol), and 0.1 g/L acetylated bovine serum albumin (BSA) was added directly to the PCR reaction mixture containing the 103-bp PCR product, and the mixture was incubated for 1 h at 65°C. For detection of Fin Minor mutation, 20 L of restriction enzyme mixture containing 3 U of AvaII enzyme (Promega), 1ϫ Buffer C (10 mmol/L Tris-HCl, pH 7.9, 50 mmol/L NaCl, 10 mmol/L MgCl 2 , and 1 mmol/L dithiothreitol), and 0.1 g/L acetylated BSA was added to the PCR reaction mixture containing the 239-bp PCR product, and the mixture was incubated for 2 h at 37°C. After the digestion, the analyses were completed by electrophoresis in a 2.5% agarose gel.
dual-color pcr-ola for detection of the Fin Minor and Fin Major mutations
For PCR-OLA, the target DNA in exons 2 and 26 of the NPHS1 gene was simultaneously amplified by PCR. The dual-PCR reaction mixture was similar to the PCR mix- ture for the PCR-RFLP, but contained the amplification primers for both the Fin Minor and the Fin Major mutation sites and 1.0 mmol/L MgCl 2 in a reaction volume of 30 L. The PCR program consisted of an initial temperature cycle of 95°C for 5 min, 85°C for the time needed to add the enzyme, 60°C for 1 min, and 68°C for 2 min, followed by 30 cycles of 94°C for 1 min, 60°C for 1 min, 68°C for 2 min, and a final extension of 68°C for 8 min.
The PCR mixtures containing the 491-bp (exon 2) and 611-bp (exon 26) PCR products were diluted 1:10 with 1 mL/L Triton X-100. The ligation reactions contained 10 L of the 1:10-diluted PCR product mixture, 0.15 pmol of each allele-specific and reporter probe, 1.2 U of thermostable ligase (New England Biolabs), and 1ϫ NE Buffer [20 mmol/L Tris-HCl (pH 7.6 at 25°C), 20 mmol/L potassium acetate, 10 mmol/L magnesium acetate, 10 mmol/L dithiothreitol, 1 mmol/L NAD ϩ , and 1 mL/L Triton X-100] in a total volume of 30 L. The reaction mixtures were subjected to 10 cycles of 97°C for 30 s and 63°C for 2 min, and stopped by the addition of 15 L of 1 mL/L Triton X-100 containing 0.1 mol/L EDTA. All pipetting steps in the OLA and ELISA were performed using an 8-channel pipette (Biohit) or a Tecan Genesis RSP 150 automated pipetting device (Tecan).
For the assay readout, the reaction mixtures were transferred into the wells of a streptavidin-coated, BSAblocked microtiter plate, and the biotin-labeled allelespecific oligonucleotides were allowed to bind to the streptavidin for 45 min at room temperature. The PCR products and unligated reporter oligonucleotides were removed from the wells by washing the plate first with 10 mmol/L NaOH containing 0.5 mL/L Tween 20 and then with a washing buffer containing 140 mmol/L NaCl, 0.5 mL/L Tween 20, 10 mmol/L Tris-HCl, pH 7.4. Antidigoxigenin-alkaline phosphatase (Roche) and anti-fluorescein-horseradish peroxidase (Roche) diluted 1:2500 with the washing buffer containing 10 g/L BSA were added to the wells and incubated 2 h at room temperature. The plate was washed with the washing buffer, and the ELISA amplification system (Life Technologies) was used for detection of the Fin Major allele. The plate was measured with a Tecan Spectrafluor spectrophotometer (Tecan) at 510 nm. To detect the Fin Minor allele, the plate was washed, the ABTS substrate (Zymed) was added, and the absorbance was measured at 405 nm. The absorbance of the blank well (no DNA in PCR) was subtracted from the absorbance values of the sample wells. The ratio of the absorbance of the wild-type (WT) allele-specific reaction to the mutant allele-specific reaction was calculated to determine the genotype. DNA samples from a patient homozygous for the Fin Major allele or the Fin Minor allele were used as controls in every PCR-OLA series.
pcr-ola for detection of the g3315a polymorphism
The DNA region containing the G3315A polymorphism in exon 26 was amplified by PCR using the same conditions as for the RFLP analysis of the Fin Minor mutation. The ligation reactions containing the WT allele-specific or the polymorphism allele-specific probe and the reporter probe were similar to those used for the dual-OLA reactions. The ligation temperature was 58°C. After the cycles, ELISA was performed to detect the digoxigeninlabeled reporter probe as described above.
Results
The PCR-RFLP analyses for the detection of the NPHS1 Fin Major and Fin Minor mutations are shown in Fig. 1 . The PCR product of a NPHS1 patient homozygous for the Fin Major mutation is digested into two fragments of 20 and 83 bp because of the artificial restriction site of TaqI enzyme created by the PCR primer (Fig. 1, lane 1) . In the case of a WT genotype, the undigested 103-bp fragment is present (Fig. 1, lane 3) and the carrier of the Fin Major mutation can be identified by the presence of both the 83-and 103-bp fragments (Fig. 1, lane 2) . PCR amplification of DNA from a NPHS1 patient homozygous for the Fin Minor mutation (Fig. 1, lane 4) and a WT control generated a 239-bp product, which appeared slightly larger on electrophoresis. The undigested DNA fragment can be seen on the gel because of an abolished restriction site of AvaII (Fig. 1, lane 4) , whereas for a healthy control, the PCR product is digested into two fragments of 188 and 51 bp (Fig. 1, lane 6) . Heterozygous carriers of the Fin Minor mutation are identified by the presence of all the three fragments (239, 188, and 51 bp; Fig. 1, lane 5) .
During the development of PCR-OLA for the Fin Minor mutation site, the nucleotide sequence analysis revealed a silent mutation (G3315A) located 10 nucleotides upstream from the Fin Minor mutation in exon 26 of NPHS1. The nucleotide sequences of the antisense strands of the WT and the polymorphic allele are shown in Fig. 2 . The prevalence of the polymorphism in the Finnish population was estimated by analyzing 256 blood samples. Seventy-four of 256 samples showed a WT genotype (95% confidence interval, 60 -88 of 256), 70 of 256 showed a homozygous genotype for the polymorphism (95% confidence interval, 56 -84 of 256), and the remaining 112 of 256 samples (95% confidence interval, 96 -128 of 256) showed a heterozygous genotype. The prevalence of the WT allele (G3315) was 51% (95% confidence interval, 46 -55%), and the prevalence of the A3315 allele was 49% (95% confidence interval, 45-54%). The result was in overall agreement with the Hardy-Weinberg equilibrium. Because the polymorphism has such a high prevalence in the studied population, it must be taken into consideration when performing PCR-OLA. Although the polymorphism is situated in the middle of the reporter probe (Table 1) , it disturbs the ligation of the oligonucleotides, producing a weak or absent signal in ELISA. Therefore two different reporter probes, one specific for the WT sequence (G3315) and the other specific for the polymorphic sequence (A3315), were used in both ligation reactions for the detection of the WT and Fin Minor alleles in exon 26.
A schematic overview of the dual-color PCR-OLA for the detection of NPHS1 is illustrated in Fig. 3 . The dual-PCR step is followed by two separate ligation reactions ( Fig. 3 , ligation A for the WT alleles and ligation B for the mutant alleles). The covalent ligation of the oligonucleotides, which occurs in the case of the perfect complementarity between the target DNA and the oligonucleotides, is detected by the color development in ELISA. Seven possible outcomes in dual-color PCR-OLA for the detection of the NPHS1 Fin Major and Fin Minor mutations are shown in Fig. 3 . A WT individual is positive for reaction A for both of the mutation sites ( Fig. 3 , outcome 1). A NPHS1 patient homozygous for the Fin Major mutation is positive for reaction B in exon 2 and for reaction A in exon 26 ( Fig. 3, outcome 2) . Correspondingly, a patient homozygous for the Fin Minor mutation is positive for reaction A for exon 2 and for reaction B for exon 26 (Fig. 3, outcome 3) . A compound heterozygote carrying both of these mutations would give a positive reaction in each of the four reactions ( Fig. 3, outcome 4) . A carrier of either of the mutations shows a positive signal for reactions A and B in the exon involved and a positive signal for reaction A for the unaffected exon ( Fig. 3 , outcomes 5 and 6). A negative control or a sample with a failure in PCR is negative for all of the reactions (Fig. 3,  outcome 7) . In theory, two additional outcomes of the dual-color OLA are also possible: a patient homozygous for one mutation may be a carrier of the other mutation.
For the PCR-OLA numeric readout, the blank absorbance value was subtracted from the absorbance of the samples and the ratio of the absorbance for the WT reaction to that of the mutant reaction was calculated for both of the mutations separately in each sample. For PCR amplification of the target DNA sequences in exon 2 and exon 26 of the NPHS1 gene is followed by ligation of the biotinylated (B) allele-specific oligonucleotides and the fluorescein (F) or digoxigenin (D)-labeled reporter probes. Ligation A is specific to WT alleles, whereas ligation B is specific to mutant alleles. The biotinylated probes are captured on streptavidin-coated microtiter wells, and the presence of the covalently linked oligonucleotides in the wells is detected using ELISA. Possible outcomes of the assay include a WT individual (outcome 1), a NPHS1 patient homozygous for the Fin Major allele (exon 2, outcome 2) or Fin Minor allele (exon 26, outcome 3), a compound heterozygote carrying both of these alleles (exons 2 and 26, outcome 4), a carrier of the Fin Major allele (exon 2, outcome 5) or the Fin Minor allele (exon 26, outcome 6), and a negative control or a sample with failure in PCR (exons 2 and 26, outcome 7). samples homozygous for the WT allele, the absorbance ratio of the A and B reactions was Ͼ5, whereas samples homozygous for the mutant allele produced a ratio of the A and B reactions Ͻ0.2. A carrier of the mutation is detected by an absorbance ratio of the A and B reactions of Ͼ0.2 but Ͻ5 for the exon involved. For both the Fin Major mutation site in exon 2 and the Fin Minor mutation site in exon 26, the absorbance ratio of the WT reaction to the mutant reaction (A/B) in samples from healthy individuals was significantly higher than the corresponding ratio in samples with the heterozygous genotype (P Ͻ0.001, Mann-Whitney U-test).
The 2.5th, 50th (median), and 97.5th percentile absorbance values of the WT genotype and the carriers of the Fin Major allele or the Fin Minor allele along with the absorbance ratios of the WT reaction (A) to the mutant reaction (B) are shown in Table 2 . Among 2004 Finnish blood samples, we found 35 carriers of NPHS1, of whom 34 individuals were carriers of the Fin Major allele and 1 was a carrier of the Fin Minor allele. All of the samples showing the carrier genotype and 5% of the samples of the WT genotype were also analyzed using PCR-RFLP, and the results of these two separate assays were in perfect concordance. The calculated carrier frequency of the NPHS1 Fin Major allele in the Finnish population was 1:59 (95% confidence interval, 1:89 -1:44) and that of the Fin Minor allele was 1:2004 (95% confidence interval, 0 to 1:677). The rates of homozygosity for the NPHS1 Fin Major and Fin Minor mutations predicted from the carrier frequencies observed in the present study were 1:13 900 (95% confidence interval, 1:31 700 -1:7740) and 1:16 100 000 (95% confidence interval, 0 to 1:1 830 000), respectively, under the Hardy-Weinberg conditions. Because the Fin Major and Fin Minor mutations account for 94% of all mutations causing NPHS1 in the Finnish population, the predicted combined carrier frequency of NPHS1 was 1:54 (95% confidence interval, 1:80 -1:41) and the frequency of NPHS1 patients was 1:11 700 (95% confidence interval, 1:25 600 -1:6720) in the population.
We also studied all of the carriers of the NPHS1 Fin Major mutation (n ϭ 34), the single carrier of the NPHS1 Fin Minor mutation, and two NPHS1 patients (one homozygous for the Fin Major mutation and the other homozygous for the Fin Minor mutation) for the presence of the A3315 polymorphism. We found that 17 of 34 carriers of the Fin Major mutation were also carriers of the polymorphism and that 4 of 34 were homozygous for the polymorphism. Based on this result, the frequency of the polymorphism allele is lower among the carriers of the Fin Major mutation (37%; 95% confidence interval, 25-48%) than among the rest of the population. The carrier of the Fin Minor mutation was also a carrier of the polymorphism, but neither of the NPHS1 patients carried the polymorphism.
Discussion
The prenatal diagnosis of NPHS1 has been based on the clinical features of the fetus and measurement the ␣-fetoprotein concentration in maternal serum or amniotic fluid. The two most common mutations that cause NPHS1 cover Ͼ94% of the NPHS1 chromosomes in the Finnish population (6 ) , thus enabling the specific prenatal or neonatal diagnosis of 88% of NPHS1 cases by detection of those two mutations. Moreover, detection of the carriers of these mutations can be used to identify couples at risk of having a child affected by NPHS1. The Fin Major and Fin Minor mutations seem to be rare in other populations because among 35 NPHS1 patients from North America, North Africa, and Europe, only 2 Swedish and 4 Finnish patients had the mutations (9 ) .
PCR-RFLP can be used for the detection of mutations that cause the elimination or creation of a restriction site (10 ) . The detection of the Fin Minor allele is achieved by detecting the elimination of the naturally occurring AvaII site, but the detection of the Fin Major allele requires creation of an artificial restriction site for TaqI enzyme by the addition of a mismatch to the PCR primer. PCR-RFLP is a highly specific method, but the lack of automation makes it inefficient for analyzing large sets of samples.
PCR-OLA assay has many advantages in the detection of characterized mutations in large-scale screening programs (8 ) . The use of several haptens enables the detection of several mutations in a single well, further increasing the throughput of the assay (11 ) . Dual-color PCR-OLA with ELISA-based detection has been used previously for the genotyping of diallelic sequence variations (11 ) and the detection of mutations in the human immunodeficiency virus (12 ) . This methodology has now been applied to the detection of the Fin Major allele located in exon 2 and the Fin Minor allele located approximately 20 kb downstream in exon 26 of the NPHS1 gene. For the simultaneous detection of these alleles, the optimization of the PCR-OLA was required. It was necessary to use 1.0 mmol/L MgCl 2 in the PCR reaction mixture and to add the DNA polymerase after the first prolonged denaturation step to prevent nonspecific amplification. Moreover, performing the elongation step at 68°C instead of 72°C was found to improve amplification. Despite successful amplification in PCR, a weak or absent signal was detected in some samples for the WT allele at the Fin Minor site when primers based on the WT sequence at that region (6 ) were used. The reason for the failure in OLA was found to be a neutral polymorphism (G3315A) in the region of reporter probe. The polymorphism affects the third base of a codon and has no effect on the amino acid sequence. However, it precludes the ligation of the oligonucleotides in OLA. This polymorphism has a very high prevalence in the studied population (allele frequency of 49%; 95% confidence interval, 45-54%). To obtain a positive signal for all of the amplified samples, equal amounts of two different reporter probes, one specific for the WT sequence (G3315) and the other specific for the sequence containing the A3315 polymorphism, were used in both ligation reactions.
The analysis of the A3315 polymorphism allele among the carriers of the NPHS1 Fin Major mutation revealed that its frequency is lower among the carriers of the Fin Major mutation (37%; 95% confidence interval, 25%-48%) than among those negative for the mutation. DNA samples from NPHS1 patients homozygous for the Fin Major and the Fin Minor mutations are needed to accurately determine the polymorphism frequency on mutant chromosomes.
The detected carrier frequency (1:59; 95% confidence interval, 1:89 -1:44) for the NPHS1 Fin Major allele was similar to the previously reported frequency (6 ) . This is higher than the carrier frequency of the major mutations that cause aspartylglycosaminuria or infantile neuronal ceroid lipofuscinosis in the Finnish population (1:94 -1:83 and 1:95, respectively) (13) (14) (15) . The detected carrier frequency for the Fin Minor allele, 1:2004 (95% confidence interval, 0 to 1:677), is lower than the frequency reported in a study of 49 patients (6 ) . This may be attributable to local differences in the occurrence of the NPHS1 alleles in the Finnish population. Our results show that the Fin Major allele is the prominent NPHS1 allele in eastern Finland, where the samples for this study were collected. The calculated frequency of NPHS1 carriers in the studied population, assuming that 94% of the NPHS1 mutations are Fin Major and Fin Minor mutations (6 ), would be 1:54 (95% confidence interval, 1:80 -1:41), predicting an incidence of 1:11 600 (95% confidence interval, 1:25 600 -1: 6720) for NPHS1. This incidence corresponds to earlier studies among Finnish population (1, 2 ) , but for reasons as yet unknown, it is much lower than the incidence of NPHS1 cases (1:2400) detected in eastern Finland by prenatal ␣-fetoprotein screening (4, 5 ) . These data give further evidence that there may be local differences in the distribution of the NPHS1 alleles and that other mutations may be present in the population of eastern Finland.
